Gruppo Oncologico Italiano di Ricerca Clinica   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Milan Italy (2015)

Organization Overview

First Clinical Trial
2015
NCT00502034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GOIRC - Gruppo Oncologico Italiano di Ricerca Clinica | Gruppo Oncologico Italiano di Ricerca Clinica

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 3)

Colorectal Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 3)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 3)

Mesothelioma (Phase 2)

Pancreatic Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Thromboembolism (Phase 4)

Venous Thromboembolism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 23